Eczema trials recruiting in Kentucky

All Eczema trials nationally

Cities in Kentucky

Recruiting trials in Kentucky

• A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
  NCT07277660 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
  NCT07003425 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
  NCT07690371 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Kentucky: Bowling Green, Owensboro
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
  NCT06389136 · Phase: Phase 3 · Ages: 18 Years to 63 Years · Sex: All (male and female) · Kentucky: Louisville
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
  NCT06461897 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female) · Kentucky: Bowling Green
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  NCT06241118 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
  NCT06947993 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Kentucky: Louisville
• Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07298395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Kentucky: Louisville